Annals of Surgical Oncology

, Volume 15, Issue 3, pp 745–753 | Cite as

Swedish Experience with Peritonectomy and HIPEC. HIPEC in Peritoneal Carcinomatosis

  • B. L. van Leeuwen
  • W. Graf
  • L. Pahlman
  • H. Mahteme
Gastrointestinal Oncology

Abstract

Background

Peritonectomy with heated intraperitoneal chemotherapy (HIPEC) has shown a survival benefit in selected patients with peritoneal carcinomatosis. This prospective non-randomized study was designed to identify factors associated with postoperative morbidity and survival after peritonectomy HIPEC in patients with this condition.

Method

Data were prospectively collected from all patients with peritoneal carcinomatosis treated by means of peritonectomy and HIPEC at Uppsala University Hospital between October 2003 and September 2006. Depending on the primary tumor, mitomycin C or a platinum compound was used as a chemotherapeutic agent for perfusion.

Results

A total of 103 patients were treated. Primary tumors were pseudomyxoma peritonei (47 patients), colorectal cancer (38 patients), gastric cancer (6 patients), ovarian cancer (6 patients) and mesothelioma (5 patients). Postoperative morbidity was 56.3% and was significantly lower in patients treated with mitomycin C for pseudomyxoma peritonei (42%) than in those with another diagnosis treated with platinum compound (71%, < 0.05). Postoperative mortality was less than 1%. At 2 years, overall survival was estimated to be 72.3%, and disease-free survival was 33.5%. Factors influencing overall and disease-free survival were tumor type and optimal cytoreduction.

Conclusion

Postoperative morbidity is dependent mainly on a tumor type; however, the chemotherapeutic agent used might also influence morbidity. Survival is determined by optimal cytoreduction and tumor type. Irrespective of age, patients with good performance status benefit from this treatment.

Keywords

Peritonectomy HIPEC Peritoneal carcinomatosis 

Notes

Acknowledgements

This work was supported by the Dutch Cancer Foundation and the Uppsala University Hospital (ALF-medel), Sweden.

References

  1. 1.
    Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000; 88:358–63PubMedCrossRefGoogle Scholar
  2. 2.
    Gonzalez-Moreno S. Peritoneal surface oncology: a progress report. Eur J Surg Oncol 2006; 32:593–6PubMedCrossRefGoogle Scholar
  3. 3.
    Murphy EM, Sexton R, Moran BJ. Early results of surgery in 123 patients with pseudomyxoma peritonei from a perforated appendiceal neoplasm. Dis Colon Rectum 2007; 50:37–42PubMedCrossRefGoogle Scholar
  4. 4.
    Smeenk M, Verwaal VJ, Antonini N, et al. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg 2007; 245:104–9PubMedCrossRefGoogle Scholar
  5. 5.
    Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Ann Surg Oncol 2007; 14:128–33PubMedGoogle Scholar
  6. 6.
    Raspagliesi F, Kusamura S, Campos Torres JC, et al. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan. Eur J Surg Oncol 2006; 32:671–5PubMedCrossRefGoogle Scholar
  7. 7.
    Piso P, Dahlke MH, Loss M, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol 2004; 2:21PubMedCrossRefGoogle Scholar
  8. 8.
    De Roover A, Detroz B, Detry O, et al. Adjuvant hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) associated with curative surgery for locally advanced gastric carcinoma. An initial experience. Acta Chir Belg 2006; 106:297–301PubMedGoogle Scholar
  9. 9.
    Fujimoto S, Takahashi M, Mutou T, et al. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 1997; 79:884–91PubMedCrossRefGoogle Scholar
  10. 10.
    Sugarbaker PH, Yan TD, Stuart OA, et al. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 2006; 32:686–91PubMedCrossRefGoogle Scholar
  11. 11.
    Begossi G, Gonzalez-Moreno S, Ortega-Perez G, et al. Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma. Eur J Surg Oncol 2002; 28:80–7PubMedCrossRefGoogle Scholar
  12. 12.
    Natarajan N, Shuster TD. New agents, combinations, and opportunities in the treatment of advanced and early-stage colon cancer. Surg Clin North Am 2006; 86:1023–43PubMedCrossRefGoogle Scholar
  13. 13.
    Sugarbaker PH. Peritonectomy procedures. Surg Oncol Clin N Am 2003; 12:703–727, XIIIPubMedCrossRefGoogle Scholar
  14. 14.
    Sarnaik AA, Sussman JJ, Ahmad SA, et al. Technology of intraperitoneal chemotherapy administration: a survey of techniques with a review of morbidity and mortality. Surg Oncol Clin N Am 2003; 12:849–63PubMedCrossRefGoogle Scholar
  15. 15.
    Van Ruth S, Verwaal VJ, Zoetmulder FA. Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am 2003; 12:771–80PubMedCrossRefGoogle Scholar
  16. 16.
    Elias DM, Sideris L. Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin N Am 2003; 12:755–69, XIVPubMedCrossRefGoogle Scholar
  17. 17.
    Elias DM, Pocard M. Treatment and prevention of peritoneal carcinomatosis from colorectal cancer. Surg Oncol Clin N Am 2003; 12:543–59PubMedCrossRefGoogle Scholar
  18. 18.
    Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol 2005; 2:3–13PubMedCrossRefGoogle Scholar
  19. 19.
    NCI DHHS DTCD. Common terminology criteria for adverse events v3.0 (CTAE). Anonymous. Anonymous. Cancer Therapy Evaluation Program, 2006Google Scholar
  20. 20.
    Glehen O, Mithieux F, Osinsky D, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 2003; 21:799–806PubMedCrossRefGoogle Scholar
  21. 21.
    Verwaal VJ, Van Tinteren H, Ruth SV, et al. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004; 85:61–7PubMedCrossRefGoogle Scholar
  22. 22.
    Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 1999; 6:790–96PubMedCrossRefGoogle Scholar
  23. 23.
    Moran BJ. Establishment of a peritoneal malignancy treatment centre in the United Kingdom. Eur J Surg Oncol 2006; 32:614–8PubMedCrossRefGoogle Scholar
  24. 24.
    Mahteme H, Hansson J, Berglund A, et al. Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. Br J Cancer 2004; 90:403–7PubMedCrossRefGoogle Scholar
  25. 25.
    Mahteme H, Graf W. Pseudomyxoma peritonei: a syndrome with varying prognosis. Läkartidningen 2003; 38:2936–40Google Scholar
  26. 26.
    Rouers A, Laurent S, Detroz B, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: higher complication rate for oxaliplatin compared to mitomycin C. Acta Chir Belg 2006; 106:302–6Google Scholar
  27. 27.
    Liberale G, Pocard M, Manganas D, et al. Hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis of digestive and peritoneal origin: rationale. Acta Chir Belg 2006; 106:291–6PubMedGoogle Scholar
  28. 28.
    Gilly FN. Phase II studies: International registry of colorectal carcinomatosis. Eur J Surg Oncol 2006; 32:648–54PubMedCrossRefGoogle Scholar
  29. 29.
    Gomez PA, Barrios P, Rufian S, et al. Management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Eur J Surg Oncol 2006; 32:628–31CrossRefGoogle Scholar
  30. 30.
    Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24:4085–91PubMedCrossRefGoogle Scholar
  31. 31.
    Verwaal VJ, Van Ruth S, Witkamp A, et al. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2005; 12:65–71PubMedCrossRefGoogle Scholar
  32. 32.
    Cavaliere F, Valle M, De Simone M, et al. 120 peritoneal carcinomatoses from colorectal cancer treated with peritonectomy and intra-abdominal chemohyperthermia: a S.I.T.I.L.O. multicentric study. In Vivo 2006; 20:747–50PubMedGoogle Scholar
  33. 33.
    Elias D, Benizri E, Di Pietrantonio D, et al. Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol 2007; 14:509–14PubMedCrossRefGoogle Scholar
  34. 34.
    Yonemura Y, Bandou E, Kawamura T, et al. Quantitative prognostic indicators of peritoneal dissemination of gastric cancer. Eur J Surg Oncol 2006; 32:602–6PubMedCrossRefGoogle Scholar
  35. 35.
    Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20:1248–59PubMedCrossRefGoogle Scholar
  36. 36.
    Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol 2006; 32:676–681PubMedCrossRefGoogle Scholar
  37. 37.
    Hadi R, Saunders V, Utkina O, et al. Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapy. ANZ J Surg 2006; 76:156–61PubMedCrossRefGoogle Scholar
  38. 38.
    Gilly FN, Cotte E, Brigand C, et al. Quantitative prognostic indices in peritoneal carcinomatosis. Eur J Surg Oncol 2006; 32:597–601PubMedCrossRefGoogle Scholar
  39. 39.
    Brigand C, Monneuse O, Mohamed F, et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol 2006; 13:405–12PubMedCrossRefGoogle Scholar
  40. 40.
    Witkamp AJ, de Bree E, Van Goethem R, et al. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 2001; 27:365–74PubMedCrossRefGoogle Scholar
  41. 41.
    Verwaal VJ, Van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21:3737–43PubMedCrossRefGoogle Scholar
  42. 42.
    Schmidt U, Dahlke MH, Klemnauer J, et al. Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2005; 31:53–8PubMedCrossRefGoogle Scholar
  43. 43.
    McQuellon RP, Loggie BW, Lehman AB, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2003; 10:155–62PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2007

Authors and Affiliations

  • B. L. van Leeuwen
    • 1
  • W. Graf
    • 1
  • L. Pahlman
    • 1
  • H. Mahteme
    • 1
  1. 1.Department of Surgical SciencesAkademiska Sjukhuset, Uppsala University HospitalUppsalaSweden

Personalised recommendations